Authors

Latest:

Dr Hasan on the Preclinical Efficacy of ROR1-Specific CAR T-Cells in CLL

Md Kamrul Hasan, PhD, discusses the preclinical efficacy and safety of ROR1-specific CAR T-cells in a preclinical mouse model of chronic lymphocytic leukemia.

Arutha Kulasinghe, PhD

Latest:

Dr Kulasinghe on a Study Profiling the NSCLC Tumor Microenvironment

Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.

Melissa Johnson, MD, Tennessee Oncology

Latest:

NSCLC: Overcoming Challenges

Oncology experts provide insight on screening methods available and discuss strategies that may address challenges in identification of targetable mutations/tumor profiles in non–small cell lung cancer (NSCLC).

Samilia Obeng-Gyasi, MD, MPH

Latest:

Dr Obeng-Gyasi on Neighborhood Opportunity and Mortality in Breast Cancer

Samilia Obeng-Gyasi, MD, MPH, discusses a retrospective study on neighborhood opportunity and all-cause mortality in patients with breast cancer.

Mattia D'Agostino, MD

Latest:

Dr. D'Agostino on Factors for Unsustained MRD Negativity in Multiple Myeloma

Mattia D'Agostino, MD, discusses factors that could lead to unsustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma who are transplant eligible.

Stephen Kimani, MD

Latest:

Mentoring Oncologists in the Era of Social Distancing

Mentoring is critically important to the development of young academic hematology/oncology trainees.

Alissa J. Cooper, MD

Latest:

Lung Cancer State of the Science Summit Recap | Chaired by: Isabel Preeshagul, DO, MBS

Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.

Pradnya D. Patil, MD, FACP

Latest:

Dr. Patil on Unmet Needs With the Use of Immunotherapy in NSCLC

Pradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.

Amir Goldkorn, MD

Latest:

Dr. Goldkorn on the Methods Used to Predict Chemotherapy Benefit in Bladder Cancer

Amir Goldkorn, MD, discusses the methods utilized to predict chemotherapy benefit in bladder cancer.

Daniel Moreira, MD

Latest:

Dr. Moreira on Launching the Global COVID-19 Observatory and Resource Center for Childhood Cancer

Daniel Moreira, MD, discusses the rationale for launching the Global COVID-19 Observatory and Resource Center for Childhood Cancer.

Beth N. McLellan, MD

Latest:

Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis

Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.

Millie Das, MD

Latest:

Dr Das on the ALINA Trial in Early-Stage ALK+ Lung Cancer

Millie Das, MD, discusses key trials that have advanced treatment for patients who present with non–small cell lung cancer.

Sebastian C. Schmid, MD

Latest:

Dr. Schmid on Next Steps for the RACE IT Trial in Urothelial Carcinoma

Sebastian C. Schmid, MD, discusses the future of the phase 2 RACE IT trial in urothelial carcinoma.

Tiago Biachi, MD, PhD

Latest:

Dr Biachi on the Evolving Role for Surgery in CRC

Tiago Biachi, MD, PhD, discusses the evolving role for surgery in colorectal cancer.

Judith Karp, MD

Latest:

Women in Oncology: Leukemia Therapies in Humans, for Humans

Judith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..

Isabelle Franklin

Latest:

Franklin on Strategies to Ameliorate the Effect of Social Determinants on CRC Screening Rates

Isabelle Franklin, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer.

Monzr M. Al Malki, MD

Latest:

Dr Al Malki on the Potential Use of TSC-100 and TSC-101 After Transplant in AML, ALL, and MDS

Monzr M. Al Malki, MD, discusses the potential use of TSC-100 and TSC-101 following allogeneic stem cell transplant in patients with AML, ALL or MDS.

Robert Albert Anders, MD, PhD

Latest:

Dr Anders on the Investigation of CCR4 Antagonists in Advanced Cancers

Robert Albert Anders, MD, PhD, discusses the rationale for developing CCR4 antagonists for use in patients with advanced cancers, including lymphoma and non–small cell lung cancer.

Jorge Cortes, MD, Georgia Cancer Center

Latest:

Future Management of Chronic Myeloid Leukemia

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.

Jacob E. Berchuck, MD

Latest:

Dr Berchuck on Next Steps for Evaluating a Novel Liquid Biopsy for PSMA in mCRPC

Jacob E. Berchuck, MD, shares next steps in research for a novel epigenomic liquid biopsy test for detecting PSMA in castration-resistant prostate cancer.